Search
Search Results
##search.searchResults.foundPlural##
-
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
8013PDF: 2546HTML: 2182Table 1.: 285Table 2.: 307Table 3.: 274Table 4.: 277 -
Parvovirus B19 infection in a patient with common variable immunodeficiency Parvovirus B19 infection in a patient with common variable immunodeficiency
1223PDF: 469HTML: 348 -
A SEROPREVALENCE OF HBV, HCV AND HIV-1 AND CORRELATION WITH MOLECULAR MARKERS AMONG MULTI-TRANSFUSED THALASSEMIA PATIENTS IN WESTERN INDIA Incidence of serology & molecular of HIV, HBV and HCV in thalassemia patients
1580PDF: 840HTML: 588 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3356PDF: 1713HTML: 410 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
3126PDF: 1121HTML: 5679 -
CANDIDA ASSOCIATED BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOLOGY PATIENTS: SINGLE CENTER EXPERIENCE
4595PDF: 1011HTML: 1378Table1: 301 -
Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia
956PDF: 660HTML: 227 -
IRON DEFICIENCY ANAEMIA AMONG PRE-SCHOOL CHILDREN WITH SICKLE CELL ANAEMIA: STILL A RARE DIAGNOSIS?
1588PDF: 903HTML: 2968cover leer: 198 -
-
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2170PDF: 2052HTML: 813 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2912PDF: 914HTML: 15044Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 413 -
HEMATOLOGICAL ABNORMALITIES BEYOND LYMPHOCYTOSIS DURING INFECTIOUS MONONUCLEOSIS: EPSTEIN-BARR VIRUS-INDUCED THROMBOCYTOPENIA THROMBOCYTOPENIA DURING INFECTIOUS MONONUCLEOSIS
2547HTML: 695PDF: 1460 -
How I treat acute and persistent sickle cell pain
2182PDF: 1212HTML: 807 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
4456PDF: 2129HTML: 1979 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4745PDF: 1836HTML: 1410 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1482PDF: 1148HTML: 489 -
Should every patient with MDS get iron chelation – probably yes.
2465PDF: 1027HTML: 405 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2774PDF: 896HTML: 5408 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2775PDF: 1706HTML: 747 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3390PDF: 1483HTML: 11881 -
Monocyte HLA-Dr Expression to Monitor Immune Response and Potential Infection Risks Following Vaso-Occlusive Crises in Patients with Sickle Cell Anemia Monocyte HLA-DR expression in SCA patients
902PDF: 637HTML: 298 -
-
SICKLE CELL ANAEMIA AND MALARIA
12169PDF: 7479HTML: 24172Figures Malaria and SCK: 295 -
CURRENT ISSUES AND OPTIONS FOR HORMONAL CONTRACEPTION IN ADOLESCENTS AND YOUNG ADULT WOMEN WITH SICKLE CELL DISEASE: AN UPDATE FOR HEALTH CARE PROFESSIONALS Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease
2403PDF: 1546HTML: 1012 -
Screening and genetic diagnosis of Hemoglobinopathies in Southern and Northern Europe: Two examples
1320PDF: 541HTML: 1224Amato1: 228Figure 2 A: Prospective (grey columns) versus retrospective prevention (black columns) among indigenous couples at risk (left) and immigrant couples (right). Among immigrant couples the prevention it is still largely retrospective, while for Italian coupl: 305jdoe, : 313Figure 2 b: Prospective (grey columns) versus retrospective prevention (black columns) among indigenous couples at risk (left) and immigrant couples (right). Among immigrant couples the prevention it is still largely retrospective, while for Italian coupl: 213 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3771PDF: 1655HTML: 4569CoverLetter: 301Figure1: 313 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1661PDF: 1043HTML: 275 -
-
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3465PDF: 1812HTML: 1194







